Express News | Atea Pharmaceuticals Completes Patient Enrollment In Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir For COVID-19 In High-Risk Patients
Moomoo 24/7Mar 27 07:05 ET
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
GlobeNewswireMar 27 07:00 ET
Atea Pharmaceuticals: Balancing Promising Prospects With Clinical and Regulatory Risks
TipRanksMar 1 01:07 ET
Earnings Call Summary | Atea Pharmaceuticals(AVIR.US) Q4 2023 Earnings Conference
The following is a summary of the Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript:Financial Performance:Atea Pharmaceuticals reported an increase in R&D expenses for Q4 and full yea
moomoo AIFeb 29 09:18 ET · Conference Call
Q4 2023 Atea Pharmaceuticals Inc Earnings Call
Yahoo FinanceFeb 29 07:02 ET
Recap: Atea Pharmaceuticals Q4 Earnings
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsAtea Pharmaceuticals b
BenzingaFeb 28 16:35 ET
Atea Pharmaceuticals GAAP EPS of -$0.47 Beats by $0.03
Seeking AlphaFeb 28 16:28 ET
Press Release: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR
Dow JonesFeb 28 16:05 ET
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report
BenzingaFeb 28 06:24 ET
Atea Pharmaceuticals Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors need to know before the announcement.Analysts estimate that Atea
BenzingaFeb 27 15:01 ET
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral th
GlobeNewswireFeb 21 07:00 ET
Atea Pharmaceuticals(AVIR.US) Officer Sells US$60,914.75 in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Corcoran Andrea sold 15,843 shares of Common Stocks on Feb 1, 2024 at an average price of $3.8449 for a total value of $60,914.75.Source: Announcement What is s
moomoo NewsFeb 2 22:15 ET
Atea Pharmaceuticals(AVIR.US) Officer Sells US$218.82K in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Sommadossi Jean-Pierre sold 56,910 shares of Common Stocks on Feb 1, 2024 at an average price of $3.845 for a total value of $218.82K.Source: Announcement What
moomoo NewsFeb 2 22:10 ET
Atea Pharmaceuticals(AVIR.US) Officer Sells US$60,963.02 in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Horga Maria Arantxa sold 15,870 shares of Common Stocks on Feb 1, 2024 at an average price of $3.8414 for a total value of $60,963.02.Source: Announcement What
moomoo NewsFeb 2 22:10 ET
Atea Pharmaceuticals(AVIR.US) Officer Sells US$47,904.19 in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Foster Wayne sold 12,477 shares of Common Stocks on Feb 1, 2024 at an average price of $3.8394 for a total value of $47,904.19.Source: Announcement What is stat
moomoo NewsFeb 2 22:10 ET
Atea Pharmaceuticals(AVIR.US) Officer Sells US$45,420.42 in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Vavricka John sold 11,819 shares of Common Stocks on Feb 1, 2024 at an average price of $3.843 for a total value of $45,420.42.Source: Announcement What is stat
moomoo NewsFeb 2 22:05 ET
Atea Pharmaceuticals(AVIR.US) Officer Sells US$53,913.45 in Common Stocks
$Atea Pharmaceuticals(AVIR.US)$ Officer Hammond Janet MJ sold 14,029 shares of Common Stocks on Feb 1, 2024 at an average price of $3.843 for a total value of $53,913.45.Source: Announcement What is s
moomoo NewsFeb 2 22:05 ET
KNDI, IREN and Om Are Among After Hour Movers
Seeking AlphaJan 10 16:52 ET
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
Yahoo FinanceJan 10 09:30 ET
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
Atea Pharmaceuticals Inc (NASDAQ:AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for hepati
BenzingaJan 9 13:33 ET
No Data
No Data